

—Inflation Reduction Act Research Series—

Imbruvica: Medicare Enrollee Use and Spending

This Fact Sheet provides information on **Imbruvica**, one of the 10 drugs selected for the first cycle of Medicare drug price negotiations. Imbruvica (active ingredient imbrutinib) is a small molecule drug used to treat blood cancers.

- Between 2018 and 2022, average annual total Part D spending per enrollee taking Imbruvica (i.e., the total amount, including Medicare, plan, and enrollee payments, spent on Imbruvica per person) increased by 51 percent (from \$85,128 to \$128,548).
- From 2018 through 2022, the average annual out-of-pocket spending per enrollee increased by 36 percent (from \$3,854 to \$5,247).

Table 1 presents data on utilization and spending for Imbruvica among Part D enrollees. About 22,000 Part D enrollees filled prescriptions for Imbruvica in 2022. Relative to the total Part D population, a greater share of Imbruvica users were men (58 percent vs. 44 percent), ages 75 or older (51 percent vs. 37 percent), and White non-Latinos (81 percent vs. 72 percent).

Table 1. Medicare Part D Use and Spending on Imbruvica, Calendar Year (CY) 2022

	Total Enrollees	LIS Enrollees ^a	Non-LIS Enrollees
Number of Part D Enrollees	53,063,000	14,957,000	38,106,000
Number of Enrollees Taking Imbruvica	22,000	4,000	18,000
Share of Part D Enrollees Taking Imbruvica	<0.1	<0.1	<0.1
Total Spending on Imbruvica			
Total Spending	\$2,854,029,000	\$574,326,000	\$2,279,703,000
Average per Enrollee taking Imbruvica	\$128,548	\$130,529	\$128,059
Enrollee Out-of-Pocket Spending on Imbruvica			
Total OOP Spending	\$116,489,000	\$823,000	\$115,666,000
Average OOP per Enrollee taking Imbruvica	\$5,247	\$187	\$6,497

Notes: ^aFor eligible Part D enrollees who meet income and asset requirements, the Low-Income Subsidy (LIS), also known as Extra Help, provides assistance with premiums, deductibles, and co-payments for covered Part D drugs.

The Inflation Reduction Act was signed into law by President Biden in August 2022. Please see [here](#) for more information on how the law is reducing drug costs for Medicare beneficiaries.

Please see [here](#) for more information on Imbruvica and the other drugs selected for the first cycle of Medicare drug price negotiation, cautions and limitations in interpretation and use of these estimates, and relevant citations.